Daxor Corporation (NASDAQ:DXR) Sees Large Growth in Short Interest

Daxor Corporation (NASDAQ:DXR) saw a significant growth in short interest in August. As of August 31st, there was short interest totaling 592 shares, a growth of 93.5% from the August 15th total of 306 shares. Based on an average daily volume of 3,474 shares, the short-interest ratio is currently 0.2 days. Approximately 0.0% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Daxor in a report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Daxor Trading Down 1.1%

NASDAQ DXR traded down $0.12 during trading hours on Tuesday, hitting $11.15. The company’s stock had a trading volume of 15,848 shares, compared to its average volume of 9,700. Daxor has a twelve month low of $8.56 and a twelve month high of $14.76. The stock has a fifty day moving average of $10.45 and a 200 day moving average of $10.43.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in DXR. Susquehanna International Group LLP boosted its position in shares of Daxor by 97.7% in the 2nd quarter. Susquehanna International Group LLP now owns 27,131 shares of the company’s stock worth $275,000 after purchasing an additional 13,411 shares during the last quarter. Aristides Capital LLC acquired a new stake in shares of Daxor during the first quarter worth $403,000. Crescent Grove Advisors LLC bought a new stake in Daxor in the first quarter valued at about $104,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in Daxor in the first quarter valued at about $245,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in Daxor in the fourth quarter valued at about $184,000. Institutional investors and hedge funds own 1.34% of the company’s stock.

About Daxor

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.